🇺🇸 FDA
Pipeline program

Dose Escalation Doublet: Combination of NKTR-214 + nivolumab

16-214-02

Phase 2 small_molecule completed

Quick answer

Dose Escalation Doublet: Combination of NKTR-214 + nivolumab for Melanoma is a Phase 2 program (small_molecule) at NEKTAR THERAPEUTICS with 1 ClinicalTrials.gov record(s).

Program details

Company
NEKTAR THERAPEUTICS
Indication
Melanoma
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials